Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05188872 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Application of 68Ga-Pentixafor PET/CT in Primary Aldosteronism and Pre-postoperative of SAAE

StatusRecruiting
PhaseNot applicable
Started2020-09-01
View on ClinicalTrials.gov ↗

Amendment history

2026-07-19
Study Status v3
Primary completion date2024-09-01→2027-09-01
Completion date2024-09-01→2027-09-01
2023-09-15
Study Status v2
Primary completion date2023-09-01→2024-09-01
Completion date2023-09-01→2024-09-01
2022-07-27
Study Status, Sponsor/Collaborators, Contacts/Locations v1
Re-verified, no change to tracked fields
2022-01-11
Original filing
Primary aldosteronism is the most common cause of secondary hypertension. The two main types of primary aldosteronism are aldosteronoma(30%) and adrenal hyperplasia(60%). The gold standard that determines the diagnosis and treatment strategy of primary aldosteronism is adrenal vein sampling(AVS), but the success rate is only about 80%. Using CXCR4 as a probe for 68Ga-Pentixafor PET/CT imaging can guide the classification diagnosis and treatment strategy of primary aldosteronism, which is a favorable supplement to AVS. Superselective adrenal artery embolization(SAAE) and laparoscopy are the main operation treatments for primary aldosteronism. SAAE is an invasive interventional operation. It is a novel way to evaluate the changes in the structure and function of adrenal tissue pre-postoperative SAAE by using the changes in 68Ga-Pentixafor PET/CT imaging.
Trial Details
NCT Number NCT05188872
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Positron-Emission Tomography
Enrollment 100 participants
Start Date 2020-09-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-21